摘要
目的评估氟替卡松沙美特罗粉吸入剂治疗咳嗽变异型哮喘(cough variant asthma,CVA)的疗效。方法收集CVA患者86例,所有患者初始均给予8周的氟替卡松沙美特罗粉吸入剂治疗,8周后将86例患者随机分为治疗组和对照组各43例,治疗组继续用药4周,对照组不用任何治疗。比较2组患者治疗前及治疗后8周、12周呼出气一氧化氮(fractional exhaled nitric oxide,FeNO)测定值、咳嗽症状积分。结果 2组患者治疗后8周后咳嗽症状总积分、FENO值较治疗前明显下降(P<0.05),12周后治疗组咳嗽症状总积分、FENO值,均低于对照组(P<0.05)。结论氟替卡松沙美特罗粉吸入剂可快速有效改善咳嗽变异性哮喘的咳嗽症状。咳嗽症状积分和FENO值均可作为评价CVA治疗效果的监测指标,二者相比,FENO值更加有效,具有无创、简便、安全、快速、可重复的优点。
Objective To evaluate the efficacy of seretide（ fluticasone/salmeterol） in treatment of patients with cough variant asthma（ CVA）.Methods 86 CVA patients were treated with fluticasone / salmeterol propionate 8 weeks,after 8 weeks,86 patients were randomly assigned to treatment group and control group,each group with 43 patients,the treatment group continued medicine for 4 weeks,the control group without any treatment. The two groups of patients FENOmeasurement values,cough symptom score before treatment and after treatment for 8 weeks,12 weeks were compared.Results After treatment for 8 weeks,cough symptom scores and FeNOin the two groups values decreased significantly compared with those before treatment（ P〈0. 05）,12 weeks after treatment,treatment group cough product,FeNOvalues,were lower than in control group（ P〈0. 05）. Conclusion Fluticasone salmeterol powder inhalation can effectively improve the symptoms of cough cough variant asthma. Symptom score and FENOvalue can be used as a monitoring index to evaluate the therapeutic effect of CVA,and the FENOvalue is more effective,which has the advantages of non-invasive,simple,safe,rapid and repeatable.
出处
《中国生化药物杂志》
CAS
2016年第4期69-70,73,共3页
Chinese Journal of Biochemical Pharmaceutics
